The risk of treatment‐related toxicities with PD‐1/PD‐L1 inhibitors in patients with lung cancer

Documenti analoghi

• Comparative efficacy and safety of PD‐1 versus PD‐L1 inhibitors in breast cancer treatment: A systematic review and meta analysis
  di: Xintong Xie, et al.
  Pubblicazione: (2024)
• Treatment of pediatric refractory or relapsed Epstein–Barr virus‐associated hemophagocytic syndrome with PD‐1 inhibitors
  di: Shu‐Yi Guo, et al.
  Pubblicazione: (2024)
• PD‐L1 inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real‐world evidence
  di: Litang Huang, et al.
  Pubblicazione: (2024)
• MEN1 deficiency stabilizes PD‐L1 and promotes tumor immune evasion of lung cancer
  di: Cuncun Zhang, et al.
  Pubblicazione: (2024)
• Expression and prognostic significance of the PD‐1/PD‐L1 pathway in AIDS‐related non‐Hodgkin lymphoma
  di: Han Zhao, et al.
  Pubblicazione: (2024)